G-protein-coupled receptors (GPCRs) are involved in many physiological processes and are therefore key drug targets 1 . Although detailed structural information is available for GPCRs, the effects of lipids on the receptors, and on downstream coupling of GPCRs to G proteins are largely unknown. Here we use native mass spectrometry to identify endogenous lipids bound to three class A GPCRs. We observed preferential binding of phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P 2 ) over related lipids and confirm that the intracellular surface of the receptors contain hotspots for PtdIns(4,5)P 2 binding. Endogenous lipids were also observed bound directly to the trimeric Gα s βγ protein complex of the adenosine A 2A receptor (A 2A R) in the gas phase. Using engineered Gα subunits (mini-Gα s, mini-Gα i and mini-Gα 12 ) 2 , we demonstrate that the complex of mini-Gα s with the β 1 adrenergic receptor (β 1 AR) is stabilized by the binding of two PtdIns(4,5)P 2 molecules. By contrast, PtdIns(4,5)P 2 does not stabilize coupling between β 1 AR and other Gα subunits (mini-Gα i or mini-Gα 12 ) or a high-affinity nanobody. Other endogenous lipids that bind to these receptors have no effect on coupling, highlighting the specificity of PtdIns(4,5) P 2 . Calculations of potential of mean force and increased GTP turnover by the activated neurotensin receptor when coupled to trimeric Gα i βγ complex in the presence of PtdIns(4,5)P 2 provide further evidence for a specific effect of PtdIns(4,5)P 2 on coupling. We identify key residues on cognate Gα subunits through which PtdIns(4,5)P 2 forms bridging interactions with basic residues on class A GPCRs. These modulating effects of lipids on receptors suggest consequences for understanding function, G-protein selectivity and drug targeting of class A GPCRs.
First, we considered the endogenous lipids that bind directly to β 1 AR and the stabilized NTSR1(HTGH4-ΔIC3B) 7 , which were expressed in and purified from insect cells and Escherichia coli, respectively. Peaks corresponding to lipid adducts were observed for β 1 AR and for NTSR1 ( Fig. 1a and Extended Data Fig. 1a ). Collisional dissociation of protein-lipid complexes allowed us to identify two major classes of lipids bound to β 1 AR, the phosphatidylserines (PS) (34:2 and 36:2) and PI phosphates (42:5) , as well as phosphatidic acid (PA) (36:2) , which bound to NTSR1 (Extended Data Fig. 1b , c and Extended Data Table 1 ). To investigate this selectivity, we incubated NTSR1 with PA and other anionic lipids (PS and PI), a zwitterionic lipid (phosphatidylcholine (PC)), and a neutral lipid (diacylglycerol (DAG)). Analysis of the resulting native mass spectra show that NTSR1 interacts preferentially with PA, PS and PI (Extended Data Fig. 2a-e ). We did not observe apparent binding of phosphatidylglycerol (PG) to NTSR1, although PG has been reported to increase G-protein activation of NTSR1 in a nanodisc 8 . It is possible that PG affects the local net charge at the receptor-lipid interface. Similarly, β 1 AR, when incubated with detergent-solubilised PS (16:0-18:1) or phosphatidylinositol-4-phosphate (PtdIns(4)P) (18:1-18:1), showed higher affinity towards PtdIns(4)P than to PS ( Fig. 1a and Extended Data Fig. 2f, g) .
To probe the selectivity of different PI derivatives we incubated β 1 AR with equimolar ratios of PI, PtdIns(4)P, phosphatidylinositol-4,5bisphosphate (PtdIns(4,5)P 2 ) and phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P 3 ), all containing the same acyl chains (18:1-18:1). Plotting intensity of peaks corresponding to lipid-bound states in the mass spectrum, relative to those of the apo protein, showed that PtdIns(4,5)P 2 had a higher affinity than PtdIns(4)P for β 1 AR (Fig. 1b ). In the case of PtdIns(3,4,5)P 3 , which contains one more phosphate group than PtdIns(4,5)P 2 , binding to β 1 AR was reduced to a similar level as observed for PI. This demonstrates that binding is selective for the head group of PtdIns(4,5)P 2 . We performed similar experiments for NTSR1 and A 2A R, and in both cases (PtdIns(4,5)P 2 ) was found to bind with the highest affinity (Extended Data Fig. 3 ), implying that all three class A GPCRs contain preferential binding sites for PtdIns(4,5)P 2 .
We performed coarse-grained molecular dynamics (CGMD) simulations (Extended Data Fig. 4 ) to characterize the molecular nature of GPCR-PtdIns(4,5)P 2 interactions in a phospholipid bilayer environment 9 . PtdIns(4,5)P 2 molecules bound at the interface formed by the cytoplasmic loops linking transmembrane helix (TM)1, TM2, TM4 and TM7 of NTSR1; this binding was mediated via interactions between the phosphorylated inositol head group and basic protein side chains ( Fig. 1c and Extended Data Fig. 4a ). Simulation of NTSR1-PS interactions indicated that these were lower-intensity, diffuse interactions that did not compete with PtdIns(4,5)P 2 (Extended Data Fig. 4c ). Similar interactions were seen with β 1 AR, which also exhibited the capacity to interact with PtdIns(4,5)P 2 via the positively charged intracellular surfaces of TM5, TM6 and TM7 (Extended Data Fig. 4b) . A more extensive comparison of simulations for nine class A GPCRs (Extended Data Letter reSeArCH Fig. 4d ) showed that this pattern of interactions with PtdIns(4,5)P 2 at the intracellular ends of transmembrane helices is conserved, suggesting that it is structurally and/or functionally significant.
To locate preferential binding sites for PtdIns(4,5)P 2 , we performed site-directed mutagenesis on NTSR1, mutating residues that we identified as forming contacts with PtdIns(4,5)P 2 (Fig. 1d ) to residues that retain the expression and folded state of the receptor 10 . We developed a mass-spectrometry-based strategy to analyse the effect of these mutations on PtdIns(4,5)P 2 binding (Extended Data Fig. 5a ). Mutating selected Lys or Arg residues to residues of lower mass decreased the molecular weight of the receptor in comparison to the unmodified parental receptor. When incubated with PtdIns(4,5)P 2 , an equimolar solution of mutant and unmodified receptor is presented with an identical lipid environment and can be resolved by mass spectrometry. Attenuation of PtdIns(4,5)P 2 binding was observed in TM1 (35 ± 0.03%) and TM4 (70 ± 0.13%) ( Fig. 1d and Extended Data Fig. 5b) , implying that the cytoplasmic surfaces of these receptors contain hotspots for PtdIns(4,5)P 2 binding.
On the basis of the location of these sites on the cytoplasmic surface, we hypothesized that PtdIns(4,5)P 2 binding influences downstream G-protein coupling. To investigate this, we developed a mass-spectrometry-based assay in which the pentameric complex of A 2A R (A 2A R-mini-Gα s βγ-Nb35; Nb35 is a stabilizing nanobody) 11, 12 was preserved in vacuum. The heteropentamer separated into several subcomplexes following collision-induced dissociation, and PS and PI were observed to be directly bound to A 2A R at higher abundance than they were before G-protein coupling ( Fig. 2a and Extended Data Fig. 3d ). We reasoned that in receptor-Gαβγ complexes, these lipids may have a stabilizing role, thereby, in turn, increasing signalling. To investigate these effects, we measured the GTPase activity of Gα i βγ when coupled to active NTSR1 (bound to neurotensin [8] [9] [10] [11] [12] [13] in the presence or absence of PtdIns(4,5)P 2 . We found that GTP hydrolysis was enhanced to 1.3-fold in the presence of PtdIns(4,5)P 2 . Therefore, PtdIns(4,5)P 2 enhances both G-protein coupling and GTPase activity ( Fig. 2b) .
Because of the instability of the trimeric G-protein complex, it is not possible to explore the effects of lipids on coupling in an unbiased way. We therefore investigated receptor complexes formed with engineered mini-G subunits that recapitulate the increase in agonist affinity observed upon coupling with the native heterotrimeric G protein ( Fig. 2c ). We recorded mass spectra of thermostabilized β 1 AR in complex with mini-G s . We found increased association of lipids when a, Mass spectrum of β 1 AR (agonist free, green; charge state is shown) and β 1 AR adducts (red, orange). Peaks (highlighted yellow) are selected in the quadrupole and analysed by tandem mass spectrometry. Phosphatidylserine (PS) and PtdIns(4)P (PIP) were identified in the resulting mass spectra. Binding curves plotted against lipid concentration confirm preferential binding of PtdIns(4)P over PS. b, Mass spectra of β 1 AR following incubation with an equimolar solution containing PI, PtdIns(4)P, PtdIns(4,5)P 2 and PtdIns(3,4,5)P 3 . Binding curves confirm favourable binding of PtdIns(4,5)P 2 . c, CGMD simulation for NTSR1(TM86V-ΔIC3B) embedded in a lipid bilayer containing mixed PC and PtdIns(4,5)P 2 . Green spheres represent basic residues with high levels of interaction with lipids; purple surfaces represent regions with high density of occupation by PtdIns(4,5)P 2 (0.6-nm distance cut-off based on the radial distribution of coarse-grained particles). d, Left, highlighted residues are mutated in NTSR1(TM86V-ΔIC3B): TM1 (R43G, K44G and K45G; red), TM4 (R135I, R137T, K139L and K140L; orange) and TM7-H8 (R311N; green). Right, inhibition of PtdIns(4,5)P 2 binding. Data are mean ± s.d. from three independent experiments. Results indicate that mutations on the TM4 interface have a greater effect than those on the TM1 and TM7-H8 interfaces. Binding curves in a and b are plotted as mean ± s.d. of three replicates from one experiment.
Letter reSeArCH β 1 AR was in a complex with mini-G s (Fig. 2d ). The stability of the receptor-mini-G s complex allowed us to investigate the selectivity towards different subtypes of Gα subunits (G s , Gα i/o and Gα 12/13 ). We investigated the coupling of agonist-bound β 1 AR to mini-G i(s) , which was engineered from mini-G s by introducing nine mutations on the α5 helix to the corresponding residues on Gα i . We performed a similar experiment with the analogous mutant of Gα 12 , in which we transferred the mutations from mini-G s to G 12 2 . In comparison to mini-G s , there was a reduced degree of coupling with mini-G i(s) and virtually no coupling with mini-G 12 (Fig. 2d ).
To investigate the effect of PtdIns(4,5)P 2 on GPCR-mini-G s interactions, we incubated agonist-bound β 1 AR with mini-G s in the presence of lipid and compared the mass spectrometry peaks corresponding to the lipid-bound protein. Although the complex can form in the absence of lipids, or with only one bound PtdIns(4,5)P 2 , complex formation is markedly enhanced (2.7-or 4.5-fold compared to the receptor without lipid, respectively) in the presence of two or three PtdIns(4,5)P 2 molecules ( Fig. 3a, g) . We observed a similar effect in a time-course experiment in which coupling of mini-G s to β 1 AR increased by 21 ± 6% when two PtdIns(4,5)P 2 molecules were bound and by a further 12 ± 5% when three PtdIns(4,5)P 2 molecules were bound (Extended Data Fig. 6a ).
We examined the effect of PS, an anionic lipid that was endogenously bound to β 1 AR ( Fig. 1a ), on coupling of mini-G s . We performed analogous experiments using a threefold higher concentration of PS than that used in the experiments with PtdIns(4,5)P 2 to reflect the reduced affinity of β 1 AR for PS ( Fig. 3b and Extended Data Fig. 2 ). Mass spectra showed only a slight increase in the extent of mini-G s coupling as a function of PS binding. This reduced effect in comparison to PtdIns(4,5)P 2 suggests that the electrostatic interactions of the polyanionic lipid headgroups in PtdIns(4,5)P 2 , which have multiple basic sidechains, are necessary for receptor coupling (as observed for Kir channels, for example 13 ) , and that such interactions do not occur with PS.
These data indicate that additional PtdIns(4,5)P 2 , but not PS, stabilize the complex once receptor coupling has occurred. Therefore, we used potential of mean force (PMF) calculations 14 to explore the effect of PtdIns(4,5)P 2 binding on the free-energy landscape of A 2A R-mini-G s interactions 15 . Comparison of PMFs for PtdIns(4,5)P 2 -bound versus PS-bound receptor in a lipid bilayer indicates that the interaction of mini-G s with A 2A R is stabilized significantly (50 ± 10 kJ mol −1 ) in the presence of PtdIns(4,5)P 2 compared with PS ( Fig. 3c and Extended Data Fig. 6b ). The presence of PtdIns(4,5)P 2 at the interface between the receptor and mini-G s in the PMF calculation implies that PtdIns(4,5)P 2 molecules form bridging interactions to stabilize the complex.
The increase in PtdIns(4,5)P 2 binding to β 1 AR when it is coupled to mini-G s could be a result of either (i) active conformations of receptors binding more PtdIns(4,5)P 2 than their inactive counterparts, or (ii) positively charged residues in mini-G s , at the receptor-G protein interface, recruiting additional PtdIns(4,5)P 2 molecules following coupling. To investigate the dependence of PtdIns(4,5)P 2 binding on receptor conformation, we incubated PtdIns(4,5)P 2 with β 1 AR (co-purified with the agonist isoprenaline) containing an E130W mutation to stabilize ligand-free β 1 AR without affecting G-protein coupling 16 . We observed a 31 ± 1% increase in PtdIns(4,5)P 2 binding to the β 1 ARisoprenaline complex versus ligand-free β 1 AR (Extended Data Fig. 6c ). Whereas in general, transition to active states is thought to involve substantial movements of TM5 and TM6, intracellular loop (ICL)2 was also found to undergo significant changes during activation of the κ-opioid receptor 17 . These results are consistent with PtdIns(4,5)P 2 stabilizing active states of receptors via binding hotspots directly on ICL2, and, more generaly, via diffuse intracellular PtdIns(4,5)P 2 -binding sites.
To explore the second possibility, in which additional PtdIns(4,5) P 2 -binding sites form following coupling, we carried out CGMD simulations for A 2A R-mini-G s , which is, to our knowledge, the only available structure of a receptor-mini-G complex. In addition to the contacts described above, PtdIns(4,5)P 2 interacted with residues of mini-G s proximal to the lipid contacts in TM3, TM4 and TM5 of A 2A R (Fig. 3e ). To investigate the significance of these additional binding sites we used a nanobody (Nb6B9) 18 , in which the lipid-binding residues identified in mini-G s are absent 12 (Extended Data Fig. 7 Letter reSeArCH (root mean square displacement (r.m.s.d.) = 0.4-0.6 Å). Comparing PtdIns(4,5)P 2 binding to the receptor and to the receptor-nanobody complex, we found that the degree of PtdIns(4,5)P 2 binding was very similar ( Fig. 3d, g) . The absence of lipid-binding residues in Nb6B9 ( Fig. 3e ) explains the insensitivity of the receptor-nanobody complex to PtdIns(4,5)P 2 and implies that PtdIns(4,5)P 2 molecules enhance coupling via interactions that are specific to the receptor and mini-G s . Lipids such as PS, in which the polyanionic headgroups are absent, would not be able to induce this effect.
To investigate the possibility that residues specific to mini-G s , that are not present in other G proteins, mediate bridging, we investigated the effects of PtdIns(4,5)P 2 on the coupling of mini-G i(s) to agonist-bound β 1 AR. We found that coupling was increased in the presence of PtdIns(4,5)P 2 , but to a lesser extent than with mini-G s (Fig. 3f, g) . Given the established role in coupling to receptors of TM5 in Gα s (R380), together with residues identified by molecular dynamics simulation ( Fig. 3e ), and the fact that these residues are substituted in Gα i (E40, V41, K42, D216 and T380), differences in PtdIns(4,5)P 2 binding can be attributed to disruption of these PtdIns(4,5)P 2 -bridging sites. It therefore follows that PtdIns(4,5)P 2 -binding sites on Gα s, which are not present on Gα i , enable simultaneous binding of the β 1 AR to the G protein to which it has highest affinity. Consequently, we propose that PtdIns(4,5)P 2 acts as an allosteric modulator, binding to the intracellular side of the receptor, stabilizing the active state and enhancing selectivity of G-protein coupling. This coupling is then further stabilized by PtdIns(4,5)P 2 molecules bridging between the receptor and the G protein.
More generally, it has been established that the cytoplasmic face of GPCRs undergoes conserved conformational changes to allow coupling of G proteins 20 ; the cytoplasmic ends of TM5 and TM6 move outwards, and TM7 moves slightly inwards. Synthetic molecules that bind at the TM5-TM6-TM7 cytoplasmic interface act as negative allosteric modulators that inhibit the activation of GPCRs by preventing their movement and consequently reducing the affinity of agonists at the orthosteric binding pocket 21, 22 . Here we highlight another role of the cytoplasmic interface, which recruits PtdIns(4,5)P 2 , thereby stabilizing the active G-protein-bound state of the receptor. Simultaneous binding of the PtdIns(4,5)P 2 head group to both the Gα subunit and conserved TM4 residues on a number of class A receptors that are not present on class B receptors suggests the generality of this mechanism for selectively stabilizing active states of class A GPCRs (Extended Data Figs. 4d, 8 ).
As the local concentration of PtdIns(4,5)P 2 in the membrane has the potential to be modulated by different signalling pathways, such as receptor tyrosine kinases or Ca 2+ signalling, crosstalk with GPCRs through PtdIns(4,5)P 2 may represent an additional mode of regulation Relative intensity (%)
Lys140 Letter reSeArCH in the cell 23 . Further, the potential to stabilize the active conformation of G-protein-coupled receptors through the binding of potent small molecules that mimic the bridging effects of the PtdIns(4,5)P 2 head group provides a further avenue for stabilizing active states of GPCRs for therapeutic purposes. As PtdIns(4,5)P 2 is able to discriminate between different G-protein subunits, and is likely to also influence binding to β-arrestin, there are potential benefits in developing novel compounds that bind specifically to different G-protein-coupled or β-arrestin-bound states, thereby providing a new perspective for rational design of novel biased allosteric agonists.
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Constructs and proteins. We used expression plasmids for two stabilized variants of rat NTSR1 7, 24 . NTSR1(HTGH4-ΔIC3B) contains the protein sequence from amino acids 50 to 390 with deletion of ICL3 (residues 273-290) and 26 thermostabilizing point mutations. It should be noted that this construct is only 80% identical to the wild-type. NTSR1(HTGH4 43-421) contains the intact protein sequence from residues 43 to 421, with the same stabilizing mutations as NTSR1(HTGH4-ΔIC3B). Purified thermostabilized turkey (Meleagris gallopavo) β 1 AR, human wild-type A 2A R, engineered Gα s (mini-G S ) and nanobody Nb6B9 were used for mass spectrometry analysis 11, 25, 26 . The following point mutations on β 1 AR were used throughout: R68S, M90V, F327A, F338M (thermostabilizing); C116L (to increase protein expression); R284K (residue equivalent to β 2 AR designed to improve Nb80 binding); C358A (prevention of potential palmitoylation). In order to purify receptor in the unliganded state, a construct with the same thermostabilizing mutations but slightly different lengths of TM1 was introduced with an additional mutation (E130W) to stabilize the receptor. The use of an N-terminal TrxA fusion (C32S and C35S) on the receptor was necessary to confirm formation of a complex on SDS gels. Insect cell lines for receptor overexpression (Sf9 and Tni) were obtained from Invitrogen and Sf9 cells for heterotrimeric G protein production were provided by M. Hillenbrand. All cells were confirmed to be free from mycoplasma contamination. Protein expression and purification. Expression and purification of β 1 AR. M. gallopavo β 1 AR constructs (β118 and β114-E130W) were based on the previously published thermostabilized β 1 AR44-m23 construct 27 but contained only four (R68S, M90V, F327A, F338M) of the original six thermostabilizing mutations, as the two mutations on TM5 and TM6 (Y227A and A282L) were not included. The omission of these two mutations resulted in constructs that demonstrated coupling to G proteins and to G protein mimetic nanobody Nb80 along with high affinity agonist binding 25 . The constructs included E. coli Thioredoxin fused to the N terminus of TM1 and the mutations C116L to improve expression and C358A to prevent potential palmitoylation. Both constructs were expressed in Sf9 insect cells using recombinant baculoviruses prepared using the transfer vector pAcGP67B (BD Biosciences) and BacPAK6 linearized baculovirus DNA (Oxford Expression Technologies). The membrane containing the expressed receptor was solubilized and purified in 2% and 0.02% dodecylmaltoside (DDM, Generon), respectively, as described previously [27] [28] [29] . For β118, the final purification step was competitive elution from an alprenolol sepharose ligand-affinity column in 20mM Tris-HCl, ph7.4, 350 mM NaCl and 0.02% DDM supplemented with 1mM isoprenaline, so that the receptor was prepared with bound agonist ligand. The purified receptor was finally concentrated to 15 mg/ml in the alprenolol sepharose elution buffer.
β114(E130W) contained the mutation E130W, which increased functional expression of β 1 AR 16 . This mutation facilitated the preparation of highly purified active receptor without any bound ligand, as the use of a ligand-affinity chromatography step was not necessary to separate non-functional receptor. For β114(E130W), purification was performed in 0.02% DDM by Ni 2+ affinity chromatography followed by a thrombin (Sigma) protease cleavage step to remove the His tag before further purification by size-exclusion chromatography (SEC) on a Superdex Increase 200 10/300GL column (GE Healthcare) in 20mM Tris-HCl, ph7.4, 100 mM NaCl and 0.02% DDM, with final concentration to 45 mg/ml. Expression and purification of A 2A R. The human A 2A R construct (residues 1-308) was modified with a C-terminal histidine tag (His10) preceded by a TEV protease cleavage site, and by the mutation N154A to prevent N-linked glycosylation. The A 2A R was expressed in Tni insect cells using the baculovirus system. Cell membranes were prepared and solubilised with 2% lauryl maltose neopentyl glycol (LMNG, Anatrace) and the receptor was purified by Ni 2+ affinity chromatography and SEC, using a Superdex Increase 200 10/300GL column (GE) run in 20 mM HEPES pH 7.5, 100 mM NaCl, 10% (v/v) glycerol, 0.01% (w/v) LMNG and concentrated to 10 mg/ml. Purification was as described previously 11 , with the exception that the receptor was purified without addition of ligand. Expression and purification of mini-G s , mini-G i and mini-G 12 . The engineered minimal G proteins, mini-G s construct R414 25 , mini-G i construct and mini-G 12 construct 8 2 were expressed in E. coli and purified by Ni 2+ affinity chromatography, followed by cleavage of the histidine tag using TEV protease and negative purification on Ni 2+ -NTA to remove TEV and undigested mini-G protein, and finally SEC to remove aggregated protein as described elsewhere 25, 30 , with final concentration up to 100 mg/ml in 10 mM HEPES, pH 7.5, 100 mM NaCl, 10% v/v glycerol, 1 mM MgCl 2 , 1 μM GDP and 0.1 mM TCEP. Expression and purification of nanobody Nb6B9. A synthetic gene (Integrated DNA Technologies) for Nb6B9 12, 31 was cloned into the plasmid pET-26b(+) (Novagen) with a N-terminal His 6 tag followed by a thrombin protease cleavage site. Expression was in E. coli strain BL21(DE3)RIL (Agilent Technologies) and purification from the periplasmic fraction was by Ni 2+ affinity chromatography, but with the use of a thrombin (Sigma) protease cleavage step to remove the His tag before concentration to 40 mg/ml.
Preparation of receptor-G-protein complexes. Several receptor-G-protein complexes were prepared for mass spectrometry analysis. A 2A R-mini-G s βγ was prepared by incubating and co-purifying A 2A R, containing a TrxA fusion at the N-terminal, with N-ethyl-carboxamidoadenosine (NECA). The complex with trimeric G proteins complex consisted of mini-G s , Gβ, Gγ and nanobody Nb35 with receptor:G proteins:Nb35 at a 1:2:4 molar ratio to stabilize the complex. The complex was further purified by gel-filtration chromatography after overnight incubation. β 1 AR-miniG was prepared by incubating β 1 AR co-purified with isoprenaline and the different mini-G proteins (mini-G s , mini-G i(s) and mini-G 12 ) at 1:1.2 molar ratio. The incubation time was varied to capture the equilibrium of complex formation. Purification of heterotrimeric G protein. Baculovirus encoding the desired subunits (α i1 β 1 γ 1 ) was used to express the heterotrimeric G protein in Sf9 cells as previously described 32 . Cells from a 1-l expression culture were resuspended and lysed in lysis buffer (10 mM HEPES pH 7, 20 mM KCl, 10 mM MgCl 2 , 10 μM GDP, 2 mM β-mercaptoethanol, and cOmplete protease inhibitor (Roche)). The membranes were pelleted by ultracentrifugation at 108,000g for 35 min and solubilized in solubilisation buffer (50 mM HEPES pH 7, 150 mM NaCl, 10 mM MgCl 2 , 10 μM GDP, 2 mM β-mercaptoethanol, 1% decyl-β-d-maltopyranoside (DM) (w/v), 10% (v/v) glycerol, and cOmplete protease inhibitor (Roche)) for 3 h. The supernatant was collected after centrifugation at 108,000g for 35 min and incubated with 1.2 ml TALON beads (GE Healthcare) overnight. The beads were collected and washed with ten column volumes wash buffer (30 mM HEPES pH 7, 300 mM NaCl, 10 mM MgCl 2 , 25 mM imidazole pH 8, 10 μM GDP, 2 mM β-mercaptoethanol, 10% (v/v) glycerol, and 0.5% (w/v) DM), followed by another twenty columnvolume wash of wash buffer containing 40 mM imidazole (pH 8.0), and were eluted with five column volumes elution buffer (30 mM HEPES pH 7, 150 mM NaCl, 1 mM MgCl 2 , 300 mM imidazole pH 8, 10 μM GDP, 2 mM β-mercaptoethanol, 10% (v/)v) glycerol, and 0.5% (w/v) DM). The protein was further purified by a Superdex 200 Increase PC 3.2/300 column (GE Healthcare) and the protein tag was removed by incubation with human rhinovirus 3C protease (produced in house) overnight. Following buffer exchange to storage buffer (20 mM HEPES pH 7, 100 mM NaCl, 0.1 mM MgCl 2 , 4 mM β-mercaptoethanol, 10% (v/)v) glycerol, and 0.5% (w/v) DM) and reverse immoblized metal affinity chromatography (IMAC) by Ni-NTA superflow beads (GE Healthcare), G-protein complex was concentrated to at least 2 mg/ml for experimental use. NTSR1 expression. BL21 E. coli cells were transformed with the expression plasmid encoding NTSR1(HTGH4-ΔIC3B) and grown overnight at 37 °C in 20 ml 2YT medium supplemented with 1% (w/v) glucose and 100 μg/ml ampicillin. Two flasks, each containing each 1 l 2YT medium, 0.5% (w/v) glucose, and 100 μg/ml ampicillin were inoculated with 10 ml pre-culture and grown to an A 600 nm of 0.5 with shaking at 37 °C. Receptor expression was induced with 1 mM isopropylβ-d-thiogalactopyranoside (IPTG) and cells were cultivated at 28 °C overnight. Cells were harvested after overnight expression and E. coli cell pellets were resuspended in 100 ml solubilisation buffer, containing 100 mM HEPES pH 8.0, 20% (v/v) glycerol and 400 mM NaCl. Resuspended cells were frozen in liquid nitrogen and stored at −80 °C. Apo NTSR1 purification. The cell pellet was thawed at room temperature. All following steps were carried out at 4 °C. MgCl 2 (5 mM), 2 mg DNase I, 200 mg lysozyme, and 20 ml detergent mixture (0.2% (w/v) cholesteryl hemisuccinate Tris salt (CHS) and 2% (w/v) dodecyl-β-d-maltopyranoside (DDM)) were added to the thawed cell pellet. The mixture was incubated for 1 h, followed by cell lysis via mild sonication for 30 min in an ice-water bath. After cell lysis, 0.4 ml 5 M imidazole was added and the mixture was incubated for another 30 min. The suspension was centrifuged for 30 min at 28,000g. The supernatant was mixed with 5 ml TALON resin (Clontech), which had been pre-equilibrated with IMAC binding buffer (25 mM HEPES pH 8.0, 10% (v/v) glycerol, 600 mM NaCl, 0.1% (w/v) DDM and 20 mM imidazole) and incubated overnight on a rolling device. The mixture was loaded into a PD10 column (GE Healthcare) and was washed with 50 ml IMAC binding buffer. Elution of bound protein was performed with 15 ml IMAC elution buffer containing 25 mM Hepes pH 8.0, 10% (v/v) glycerol, 150 mM NaCl, 0.1% (w/v) DDM and 250 mM imidazole. Eluted receptor was concentrated in an Amicon-15 Ultra concentrator with a 100 kDa cut-off (Millipore) to a final volume of less than 2.5 ml. Concentrated receptor sample was loaded on a Sephadex G-25 desalting column (GE Healthcare), pre-equilibrated with 25 mM Hepes pH 8.0, 10% (v/v) glycerol, 150 mM NaCl, 0.1% (w/v) DDM to remove remaining imidazole. Desalted receptor was incubated with 300 μl 1.6 mg/ml HRV 3C protease for 1 h at 4 °C, followed by addition of 150 μl 10% (w/v) LMNG and incubation for 1 h at 4 °C. The cleaved protein was diluted threefold with reverse IMAC buffer (10 mM HEPES pH 8.0, 10% (v/v) glycerol, 150 mM NaCl, and 0.01% (w/v) LMNG) and was loaded onto a PD10 column containing 5 ml Ni-NTA beads pre-equilibrated with reverse IMAC buffer. The flow through was collected in an Amicon-15 Ultra concentrator with a 50-kDa cut-off and the resin was further washed with 10 ml buffer. Receptor was concentrated to a final volume of less than 1 ml and was subjected to preparative SEC using a Superdex 200 10/300 GL column (GE Healthcare), which had been pre-equilibrated with 10 mM HEPES pH 8, 150 mM NaCl, and 0.01% (w/v) LMNG. Peak fractions corresponding to NTSR1(HTGH4-ΔIC3B) were pooled (final volume 3-4 ml) and concentrated in an Amicon-4 Ultra-concentrator with a 50-kDa cut-off to a final protein concentration of approximately 50 μM. Purified and concentrated NTSR1-H4 was mixed with 10 mM HEPES pH 8, 150 mM NaCl, 0.01% (w/v) LMNG, and 50% (v/v) glycerol to yield a final glycerol concentration of 25%. Aliquots were frozen in liquid nitrogen and stored at −80 °C for later use. Preparation of phospholipids and titration experiment. Phospholipids were purchased from Avanti (Avanti Polar Lipids) and prepared as 3 mM stock solutions in 200 mM ammonium acetate buffer pH 7.5 containing the detergent-mixed micelle preparation, containing DDM and foscholine as previously described 33 . Phosphate analysis was performed to determine the concentration of phospholipids in solution 34 . For the titration experiment, 5 μM buffer-exchanged receptors in 200 mM ammonium acetate buffer pH 7.5 containing the detergent mixtures (DDM, LMNG, and foscholine for NTSR1; DDM and foscholine for β 1 AR and A 2A R) were mixed with lipids at various concentration points followed by equilibration at 4 °C for 5 min, by which time lipid binding had stabilized according to our time course measurements. Following mass spectrometry analysis, UniDec (Universal Deconvolution) software was used to quantify the relative abundance of each lipid-bound state 35 , and statistical analysis was performed using GraphPad Prism, assuming a one-site total binding model. Lipidomics analysis. Co-purified lipids from recombinant GPCRs were extracted by chloroform-methanol (2:1, v/v) and lyophilized and re-dissolved in 60% acetonitrile (ACN). For LC-MS/MS analysis, the extracted lipids were separated on a C18 column (Acclaim PepMap 100, C18, 75 mm × 15 cm; Thermo Scientific) using a Dionex UltiMate 3000 RSLC nano LC System. The buffers and gradient are adapted from a previous protocol 36 . In brief, the lipids were separated using a binary buffer system at 40 °C using a gradient of 32-99% buffer B at a flow rate of 300 nl/min over 30 min. (Buffer A: (acetonitrile: H 2 O (60:40), 10 mM ammonium formate, 0.1% formic acid) and buffer B (propan-2-ol:acetonitrile (90:10), 10 mM ammonium formate, 0,1% formic acid)). The column eluent was delivered via a dynamic nanospray source to a hybrid LTQ Orbitrap mass spectrometer (Thermo Scientific). Typical mass spectrometry conditions were: spray voltage (1.8 kV) and capillary temperature (175 °C). The LTQ-Orbitrap XL was operated in negative ion mode using data-dependent acquisition with one MS scan followed by five MS/MS scans 37 . Survey full-scan mass spectra were acquired in the orbitrap (m/z 350-2,000) with a resolution of 60,000. CID fragmentation in the linear ion trap was performed for the five most intense ions at an automatic gain control target of 30,000 and a normalized collision energy of 38% at an activation of q = 0.25 and an activation time of 30 ms. GTPase assay. The GTPase activity of trimeric Gα i βγ was measured with the GTPase-Glo assay (Promega). The assay was performed in white 384-well plates (Corning) using purified trimeric G proteins diluted into a GTPase buffer (10 mM HEPES pH 7, 50 mM NaCl, 0.05 mM MgCl 2 , 2 mM β-mercaptoethanol, 1mM DTT, 5% (v/v) glycerol, and 0.25% (w/v) DM) at a finial concentration 2.5 μM in the presence of 5 μM GTP. The luminescent signal was measured after incubation at room temperature (1 h) following the manufacturer's protocol to indicate the level of residual GTP. To analyse the impact of PtdIns(4,5)P 2 we used NTSR1(HTGH4-ΔIC3B) co-purified with recombinant neurotensin 8-13 following the method described previously 38 . The receptor was pre-incubated with detergent-solubilised PtdIns(4,5)P 2 at 1:3 molar ratio (receptor:lipid) in the protein buffer (10 mM HEPES pH 8, 150 mM NaCl, 0.01% (w/v) LMNG) containing 100 nM neurotensin [8] [9] [10] [11] [12] [13] for 15 min on ice. The activated receptor was then added to the reaction mixture containing trimeric G proteins under the condition described above. Native mass spectrometry of GPCRs. Purified GPCRs were buffer exchanged into 200 mM ammonium acetate buffer pH 7.5 containing the mixed micelle preparation optimized for GPCR analysis as described previously 6 . The concentration of DDM, foscholine and CHS required to form a mixed micelle range from 0.006-0.02%, 0-0.002%, and 0.001-0.01%, respectively, and are optimized for each receptor preparation. The samples were immediately introduced into a modified Q-Exactive mass spectrometer (Thermo), as described previously 5 . Ions were transferred into the higher-energy collisional dissociation (HCD) cell following a gentle voltage gradient (injection flatapole, inter-flatapole lens, bent flatapole, transfer multipole: 7.9, 6.94, 5.9, 4 V, respectively). An optimized acceleration voltage (100-130 V) was then applied to the HCD cell to remove the detergent micelle from the protein ions. Backing pressure was maintained at ~1.00 × 10 −9 mbar and data was analysed using Xcalibur 2.2 SP1.48.
The bound-lipid identification experiments were performed with a modified Synapt G2 mass spectrometer (Waters) equipped with a Z-spray source 33, 39 . The typical instrumental setting was source pressure (4.5-5.0 mbar), capillary voltage (1.2-1.5 kV) and cone voltage (100-200 V). An extraction voltage of 1-5 V was applied and 80-150 V was used as the collision voltage with argon as the collision gas at a pressure of 0.2-0.3 MPa. To strip the detergent from protein ions in the source region, instrument values were optimized to capillary voltage (1.5 kV), cone voltage (200 V) and extraction voltage (3 V). A collision voltage ramp (from 20-100 V) was applied to dissociate protein-lipid complexes after quadrupole selection. Identification of preferential PtdIns(4,5)P 2 -binding sites on NTSR1. Unmodified NTSR1 and NTSR1 variants were pre-incubated at 1:1 molar ratio to produce a total protein concentration of 12 mM in protein buffer (10 mM HEPES pH 8, 150 mM NaCl, 0.01% (w/v) LMNG and 25% (v/v) glycerol). Detergent solubilised PI(4,5)P 2 was then added to the protein mixture at a final molar ratio of 1.25:1 lipid:receptor. The reaction mixture was incubated at 4 °C for 5 min and analysed by mass spectrometry after buffer exchanging to 200 mM ammonium acetate buffer containing the mix of detergents of DDM, LMNG and foscholine as described previously 6 .
The ratio of PtdIns(4,5)P 2 binding to the receptor was calculated by normalizing the intensity of the receptor in PtdIns(4,5)P 2 -bound states to the unbound state using UniDec software. The results were evaluated by comparing the ratio of PtdIns (4, 5) P2 binding between mutants and the unmodified receptor and plotted as a bar chart using GraphPad Prism. Mini-G S and Nb6B9 coupling to β 1 AR. Effector coupling to β 1 AR was analysed using a modified Q-Exactive mass spectrometer after incubating purified β 1 AR with mini-G S -Nb6B9 at 1:1.2 molar ratio at 4 °C in protein buffer (20mM Tris-HCl, ph7.4, 350 mM NaCl and 0.02% DDM). The relative percentage of effector coupling was quantified by UniDec software. A time course was performed with aliquots sampled after 2, 10, 30, and 60 min to monitor the formation of the mini-G S -receptor complex. To investigate the effect of PtdIns(4,5)P 2 on coupling, β 1 AR was pre-incubated with detergent-solubilised PtdIns(4,5)P 2 at 1:1 molar ratio for 5 min at 4 °C to equilibrate before mixing with mini-G S or Nb6B9 at 1.2 or 0.3 molar ratio to receptor, respectively. For the analogous PS binding experiment we pre-incubated β 1 AR with a threefold higher concentration of detergent solubilised PS than PtdIns(4,5)P2 (PS:β 1 AR, 3:1 molar ratio) for 5 min at 4 °C to equilibrate before mixing with mini-G S. Modelling and simulation system setup. Simulations were performed using the GROMACS v.4.6.3 simulation package. Initial protein coordinates were obtained using PDB ID 4BUO (NTSR1) and PDB ID 2Y03 (β 1 AR), with missing atoms added using MODELLER 40 . In the case of β 1 AR, a model was also constructed in which S68 in the thermostabilized structure 2Y03 was back-mutated to R68 to reconstruct available basic residues in the wild-type receptor using the mutagenesis tool implemented in PyMOL v.1.3r1. Side-chain ionisation states were modelled using pdb2gmx 41 . The N and C termini were treated with neutral charge. Each protein structure was then energy minimized using the steepest descents algorithm implemented in GROMACS, before being converted to a coarse-grained representation using the MARTINI 2.2 force field 42 . The energy minimized coarse-grained structure was centred in a periodic simulation box with dimensions 11 × 11 × 12 nm 3 . POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) molecules were randomly placed around the protein and the system was solvated and neutralised to a concentration of 0.15 M NaCl. An initial 50 ns of coarsegrained simulation was applied to permit the self-assembly of a POPC lipid bilayer around the GPCR. POPC lipids were randomly exchanged 43 to create a mixedspecies bilayer of specified composition (Extended Data Table 2 ). A cut-off distance of 2.5 nm was applied, with only molecules outside this distance being subject to exchange. The exchange protocol was conducted independently for each repeat simulation, such that different random initial configurations of lipids around the protein were generated for each simulation repeat. A summary of simulations performed is provided in Extended Data Table 2 . Simulation details. The MARTINI force field 42 was used to describe all system components. An ELNEDYN network 44 was applied to the protein using a force constant of 500 kJ/mol/nm 2 and a cut off of 1.5 nm. Simulations were performed as an NPT ensemble, with temperature maintained at 310 K using a Berendsen thermostat 45 using a coupling constant of τ t = 4 ps, and semi-isotropic pressure controlled at 1 bar using a Berendsen barostat 45 with a coupling constant of τ p = 4 ps and a compressibility of 5 × 10 −6 bar -1 . Electrostatics were modelled using the reaction field coulomb type 46 , and smoothly shifted between 0 and 1.2 nm. Van der Waals interactions were treated using a shifting function between 0.9 and 1.2 nm. Covalent bonds were constrained to their equilibrium values using the LINCS algorithm 47 . Equations of motion were integrated using the leap-frog algorithm, with a 20-fs time step. All simulations were run in the presence of conventional MARTINI water, and neutralised to a concentration of 0.15 M NaCl.
Analysis of simulation data was conducted using VMD 48 , PyMOL, tools implemented in GROMACS 41 , and in-house protocols. Protein-lipid contact analysis employed a cut-off distance of 0.6 nm, based on radial distribution functions for coarse-grained lipid molecules 49 . A 2A R-mini-G S PMF calculations. PMFs for the interaction of mini-G S with A 2A R in a lipid bilayer in the presence and absence of PtdIns(4,5)P 2 were calculated using the MARTINI force field 50 . To obtain a PtdIns(4,5)P 2 -bound A 2A R-mini-G S complex,
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Extended Data Fig. 3 | Investigation of the phospholipid preferences of A 2A R and NTSR1. a, A representative mass spectrum of purified A 2A R from three independent experiments revealed truncations of the N-terminal sequence (MPIM). The arrows between species indicate the mass differences corresponding to truncated amino acids (M, PI and M). b, A competitive binding assay (n = 3 independent experiments) in which A 2A R was incubated with a mixture of lipids (PI, PtdIns(4)P, PI(4,5)P 2 , and PtdIns(3,4,5)P 3 ) before mass spectrometry, indicated that PtdIns(4,5)P 2 binds with a higher affinity than the other phospholipids to A 2A R. c, The analogous competitive binding assay, in which NTSR1 was incubated with a mixture of lipids (PI, PtdIns(4)P, PI(4,5)P 2 and PtdIns(3,4,5)P 3 ) before mass spectrometry. Ratio to apo is plotted as a function of concentration and defined as the ratio of the intensity corresponding to individual PI phosphate adducts to the receptor in the apo state (inset). The same data analysis methods are used for Fig. 1b . PtdIns(4,5)P 2 binds with a higher affinity than the other phospholipids to A 2A R. Data are shown as mean ± s.d. from three independent replicates. d, A representative mass spectrum of A 2A R (n = 3 independent experiments) used for preparation of the G-protein complex reveals lower abundance of PS and PI adducts prior to coupling to G proteins.
Extended Data Fig. 4 | NTSR1-PtdIns(4,5)P 2 and β 1 AR-PtdIns(4,5)P 2 interactions within CGMD simulations, and comparison of PtdIns(4,5) P 2 contacts among different GPCRs. a, Volumetric density surfaces showing the average spatial occupancy of PtdIns(4,5)P 2 lipids around a crystal structure of NTSR1(TM86V-ΔIC3B) (PDB: 4BUO), which shares a greater sequence identity to the wild-type receptor (91%) than NTSR1(HTGH4-ΔIC3B) (86%), contoured to show the major PtdIns(4,5) P 2 -interaction sites. Density surfaces were calculated over 5 μs of CGMD (blue surface, n = 10 independent experiments), and 100 μs of CGMD (magenta, n = 1 experiment). The cytoplasmic side of NTSR1 structure is coloured from white (low PtdIns(4,5)P 2 interaction) to red (high PtdIns(4,5)P 2 interaction). Extending a simulation to 100 μs revealed no overall change in the patterns of PtdIns(4,5)P 2 interaction. Less specific, and hence more dynamic, interaction was seen for the acyl chain moieties of PtdIns(4,5)P 2 , which yielded more diffuse probability densities. b, β 1 AR-PtdIns(4,5)P 2 interactions within CGMD simulations. Contact patterns are shown for simulations containing 5% PtdIns(4,5)P 2 in the lipid bilayer and thermostable β 1 AR (PDB: 2Y03, top), 10% PtdIns(4,5)P 2 and thermostable β 1 AR (middle), and 10% PtdIns(4,5)P 2 and β 1 AR(S68R) construct (bottom). In each case PtdIns(4,5)P 2 contacts were calculated over 5 μs of CGMD (n = 10 independent experiments; error bars, s.d.), with each repeat simulation initiated from different random system configurations. c, PS and PtdIns(4,5)P 2 contacts with NTSR1 as a function of residue position, for PC:PS membranes (top left), PC:PS:PtdIns(4,5) P 2 membranes (top right), PC:PtdIns(4,5)P 2 membrane (bottom left) and PC:PS:PtdIns(4,5)P 2 (bottom right). The position of helices is denoted by horizontal grey bars. Lipid contact is calculated as the mean number of contacts between each residue and a given lipid species per frame, using a 6 Å distance cut-off. n = 3; error bars, s.d.. d, PtdIns(4,5)P 2 contacts seen in CGMD simulations for nine class A GPCRs: histamine H1 receptor, PDB 3RZE; β 1 adrenergic receptor, 2VT4; β 2 adrenergic receptor, 2RH1; CB1 cannabinoid receptor, 5TGZ; M4 muscarinic acetylcholine receptor, 5DSG; adenosine A 2A receptor, 3EML; dopamine D3 receptor, 3PBL; sphingosine 1-phosphate receptor, 3V2W; rhodopsin, 1F88. GPCR sequences are shown, with TM helices, intracellular loops (ICL) and H8 helices indicated by horizontal bars, and with amino acids coloured according to the mean number of contacts per simulation frame with the PtdIns(4,5)P 2 molecules. Green boxes correspond to the high frequency of PtdIns(4,5)P 2 interactions discussed in the main text for the TM1, TM4, and TM7/H8 motifs of NTSR1. Contacts were computed over 1 μs CGMD simulations (n = 3 independent experiments) for each GPCR, using a 6 Å cut-off. Sequences were aligned using T-Coffee 52 and mapping of proteinlipid contact data onto the sequence alignment used ALINE 53 .
Extended Data Fig. 6 | PtdIns(4,5)P 2 binds preferentially to β 1 AR in an active state and stabilizes β 1 AR coupled to mini-G s and A 2A R-mini-G s complex. a, A time-course experiment was performed to monitor the formation of active β 1 AR-mini-G s complex. The coupling efficiency (percentage) was calculated from the relative intensity of peaks assigned to β 1 AR-mini-G s coupling in the appropriate lipid-bound state. The plot indicates that mini-G s coupling is enhanced by PtdIns(4,5)P 2 when more than two lipid molecules are bound to the receptor. Error bars represent s.d. from at least three independent experiments. b, Plot of PMF for the interaction of mini-G s with A 2A R in the presence of PtdIns(4,5)P 2 (green) or PS (grey). The PMF is calculated along a reaction coordinate (Δz) corresponding to the centre-centre separation of the mini-G s and receptor proteins along the z axis (normal to the bilayer plane). The interaction of mini-G s with the A 2A R is stabilized in the presence of PtdIns(4,5)P 2 by 50 ± 10 kJ mol −1 relative to PS. Error bars (which are <10 kJ mol −1 ) are from bootstrap sampling of the PMFs and therefore represent the 'statistical' errors in estimating the well depth from a given set of simulations and PMF calculation (n = 3 independent experiments). We therefore estimate a minimum error of ≤10 kJ mol −1 . c, Mass spectra were recorded for a 1:1 equimolar mix of an inactive unliganded β 1 AR variant, E130W, and its unmodified active counterpart (co-purified with the agonist isoprenaline) in the presence of PI(4,5)P 2 . Lipid binding occurred on both receptors, but following normalization to account for differences in ionization efficiency, a clear preference for PtdIns(4,5)P 2 binding to the active receptor was observed. Bars represent mean ± s.d.
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